Dr. Krutarth Patel, as COO, is responsible for the entire product lifecycle – from product development to post-market surveillance. With extensive experience in various diagnostics corporations, including his work at a Notified Body and his outstanding expertise in quality management, regulatory affairs and product management, he drives the implementation of innovative diagnostic solutions. His in-depth knowledge of the diagnostics industry and strategic vision ensure the successful development and positioning of the company in national and international markets.
As the discoverer of the genes TKTL1 and DNaseX, Dr. Johannes Coy is the origin of Zyagnum AG. The proteins produced by these genes and their flow cytometric detection in scavenger cells in the blood form the basis of Zyagnum AG’s early cancer detection test. Together with our CEO Ralf Schierl, he founded our company in 2007 and is still an important consultant for us today.
Ralf Schierl founded our company in 2007 together with Dr. Johannes Coy and was responsible for product and business development at Zyagnum AG as CEO until 2025. In this role and with his many years of experience in the diagnostics industry, he played a key part in shaping the vision for our company that still drives us today. Ralf Schierl continues to serve as an important advisor to us.
“The early detection of cancer via the body’s own immune system could make a significant contribution to increasing the chances of recovery for affected patients. Monocytes play an important role here as a monitoring system and their examination in the blood makes it possible to determine whether monocytes have had contact with tumor cells. This has already been shown several times in publications and the further development of the test could lead to the detection of tumors at an early stage based on their degenerated metabolism.”
“I am happy to make my medical and scientific expertise available for the development of a promising new approach to the early diagnosis and treatment of cancer.”